Zimbabwe has turned down a major US health deal valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' insistence on sensitive biological samples.
This move came to light after a official document dated December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
A government representative has since explained that the United States was demanding access to genetic material for research and commercial gain while was not willing to guarantee the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued negotiations to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Implications
This rejection comes after a similar case in neighbouring Kenya, where a high court blocked a related deal with the US following concerns were raised about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking government-to-government agreements to boost transparency and accountability.
Based on statements, 16 African countries have to date signed similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no equivalent promise of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens should a future disease outbreak arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending frameworks previously set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is designed to guarantee that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation could be structured in a way that honours the independence and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that talks should continue considering much of the country's Aids initiatives relied on international support.
"In cases where technical issues arise, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it added.
The situation underscores the ongoing debate between accepting much-needed international aid and protecting a country's data in an ever more interconnected world.